News

RemeGen Raises $100M to Advance Potential Lupus Treatment, RC18

RemeGen has received $100 million in private financing to continue advancing RC18 (telitacicept), its lead treatment candidate for autoimmune diseases like systemic lupus erythematosus (SLE) now in a pivotal clinical trial. The funding will also support the China-based company’s early stage treatment discovery platform, help expand its manufacturing…

Voclosporin for Lupus Nephritis Under ‘Rolling’ Review by FDA

Aurinia Pharmaceuticals announced the start of a rolling submission of its application requesting that voclosporin be approved in the U.S. to treat people with lupus nephritis. In a rolling submission, completed portions of a New Drug Application (NDA) are submitted for review by the U.S. Food and Drug Administration…

Acthar Gel Eases SLE Exacerbations and Symptoms, Study Reports

Treatment with Acthar Gel (repository corticotropin injection) may ease exacerbations and symptoms in people with systemic lupus erythematosus (SLE) and other inflammatory disorders, a real-world study reports. About 95% of those with SLE showed benefits, as rated by physicians. The study, “…

Patient-reported Lupus Flares Linked to Disease Severity, Survey Finds

Taking into account patient-reported lupus flares in clinical practice may help assess disease severity and the economic impact of the disease, including loss of work productivity and hospital care, according to a recent study. Current measurements of flares do not include a patient’s own perspective. That…